Innoviva (INVA) Long-Term Deferred Tax (2011 - 2025)
Innoviva's (INVA) quarterly Long-Term Deferred Tax came in at $8.0 million in Q3 2025, down 46.34% YoY from $14.9 million in Q3 2024, and down 38.27% on a QoQ basis from $12.9 million in Q2 2025.
Analysis
Innoviva (INVA) Long-Term Deferred Tax (2011 - 2025) Analysis & Trends
Innoviva (INVA) has 10 years of Long-Term Deferred Tax data on file, last reported at $8.0 million in Q3 2025.
- Quarterly Long-Term Deferred Tax fell 46.34% year-over-year to $8.0 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $8.0 million (down 46.34% YoY) and the FY2025 annual result came in at $8.0 million, down 46.34% from the prior year.
- Long-Term Deferred Tax declined to $8.0 million in Q3 2025, from $12.9 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $74.0 million in Q1 2021 to a low of $5.0 million in Q3 2023.
- A 5-year average of $21.2 million and a median of $13.9 million in 2024 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2021 — Long-Term Deferred Tax slumped 81.52% — and 2024, when it jumped 200.38%.
- Tracing INVA's Long-Term Deferred Tax over 5 years: stood at $17.3 million in 2021, then jumped by 34.32% to $23.3 million in 2022, then sank by 78.72% to $5.0 million in 2023, then surged by 143.42% to $12.1 million in 2024, then sank by 33.78% to $8.0 million in 2025.
- The last three Long-Term Deferred Tax figures came in at $8.0 million (Q3 2025), $12.9 million (Q2 2025), and $12.3 million (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 7.98 Mn |
| Jun 30, 2025 | 12.93 Mn |
| Mar 31, 2025 | 12.29 Mn |
| Dec 31, 2024 | 12.05 Mn |
| Sep 30, 2024 | 14.88 Mn |
| Jun 30, 2024 | 11.45 Mn |
| Sep 30, 2023 | 4.95 Mn |
| Jun 30, 2023 | 6.33 Mn |
| Jun 30, 2022 | 23.27 Mn |
| Mar 31, 2022 | 22.40 Mn |
| Dec 31, 2021 | 17.33 Mn |
| Sep 30, 2021 | 28.16 Mn |
| Jun 30, 2021 | 48.69 Mn |
| Mar 31, 2021 | 74.02 Mn |
| Dec 31, 2020 | 93.76 Mn |
| Sep 30, 2020 | 109.49 Mn |
| Jun 30, 2020 | 118.35 Mn |
| Mar 31, 2020 | 138.24 Mn |
| Dec 31, 2019 | 154.17 Mn |
| Sep 30, 2019 | 166.56 Mn |